![Phase 1 data from the auristatin HER2 ADC PF-06804103 highlight the importance of optimizing the toxicity profile of novel ADCs – Paolo Tarantino](https://oncodaily.com/pub/uploads/2023/06/Paolo-Tarantino-1-1280x1280.jpeg)
Photo from Paolo Tarantino/Twitter
Jul 9, 2023, 09:59
Phase 1 data from the auristatin HER2 ADC PF-06804103 highlight the importance of optimizing the toxicity profile of novel ADCs – Paolo Tarantino
Phase 1 data from the auristatin HER2 ADC PF-06804103 highlight the importance of optimizing the toxicity profile of novel ADCs. The drug showed relevant activity (ORR 30%) for HER2+ BC & GC, but nearly half of the pts discontinued treatment for toxicity.
For article: Click here
Source: Paolo Tarantino/Twitter